Skip to main content
Sign In
 

Philip L. Simonian, MD - Assistant Professor

Division of Allergy and Clinical Immunology


Division of Pulmonary Sciences and Critical Care Medicine

 

12700 East 19th Avenue, B164
Aurora, CO 80045
Phone: 303-724-7198
Fax: 303-724-7212
Philip.Simonian@ucdenver.edu

 

 

1984-88 BA (Biology) University of Rochester, Rochester, NY

1990-94 MD, Northwestern University School of Medicine, Chicago, IL

1994-97 Research Fellow (Immunology) University of Michigan, Ann Arbor, MI

1997-2000 Internship/Residency (Internal Medicine) Northwestern University, Chicago, IL

2001-2004 Fellowship (Pulmonary/Critical Care) University of Colorado, Denver, CO

 

Board Certification:

American Board of Internal Medicine

                Diplomate in Internal Medicine, 2000

                Diplomate in Pulmonary Disease, 2003

                Diplomate in Critical Care Medicine, 2006

My clinical interest is the pulmonary manifestations of autoimmune diseases such as scleroderma, rheumatoid arthritis and systemic lupus erythematosus as well as pulmonary fibrosis associated with interstitial lung diseases and acute lung injury.

Pulmonary Clinic

 

Clinic Location:

University of Colorado Hospital

General Pulmonary Clinic

Anschutz Outpatient Pavilion, 7th Floor

1635 Aurora Court

Aurora, CO 80045

Ph 720-848-0768 Fax 720-848-0750

 

Clinic Days:

Wednesday Mornings

 

Appointment Contact:

720-848-0748

For more information please see Dr. Simonian's profile at CUDoctors.com.

 

My research focuses on the mechanisms of inflammation-induced pulmonary fibrosis related to chronic exposure to inhaled antigen.  The goal of our research is to identify pathogenic and protective T cells and define the mechanisms by which they exert their function.

 

Research Team:

Fabian Wehrmann, MD

Simonian PL, Roark CL, Wehrmann F, Lanham AK, Born WK, O’Brien RL and Fontenot AP.  IL-17A expressing T cells are essential for bacterial clearance in a murine model of hypersensitivity pneumonitis.  J Immunol. 2009; 182:6540-6549.

Simonian PL, Roark CL, Wehrmann F, Lanham AK, Diaz del Valle F, Born WK, O’Brien RL and Fontenot AP.  Th17 polarized immune response in a murine model of hypersensitivity pneumonitis and pulmonary fibrosis.  J Immunol.  2009; 182:657-665.

Simonian PL, Roark CL, Born WK, O’Brien RL and Fontenot AP.  γδ T cells and Th17 cytokines in hypersensitivity pneumonitis and lung fibrosis. Transl Res.  2009; 154(5):222-7.

Roark CL, Simonian PL, Fontenot AP, Born WK and O’Brien RL.  γδ T cells: an important source of IL-17.  Curr Opin Immunol.  2008; 20(3):353-357.

Simonian PL, Roark CL, Diaz del Valle F, Palmer BE, Douglas IS, Ikuta K, Born WK, O’Brien RL and Fontenot AP.  Regulatory role of γδ T cells in the recruitment of CD4+ and CD8+ to lung and subsequent pulmonary fibrosis.  J Immunol.  2006; 177:4436-4443.

Sullivan AK, Simonian PL, Falta MT, Cosgrove GP, Brown KK, Kotzin BL, Voelkel NF and Fontenot AP.  Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am. J. Respir. Crit. Care Med.  2005; 172:590-596.

Simonian PL, Grillot DA and Nunez G.  Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death.  Blood.  1997; 90:120-1216.

Simonian PL, Grillot DA, Merino R and Nunez G.  Bax can antagonize Bcl-XL during chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL.  J Biol Chem.  1996; 271:22764-22772.

Simonian PL, Grillot DA, Andrews DW, Leber B and Nunez G.  Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death. J Biol Chem.  1996; 271:32073-32077.

Simonian PL, Grillot DA and Nunez G.  Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and Bcl-2.  Oncogene.  1997; 15:1871-1875.

Merino R, Grillot DA, Simonian PL, Muthukumar S, Fanslow WC, Bondada S and Nunez G.  Modulation of anti-IgM-induced B cell apoptosis by Bcl-XL and CD40 in WEHI-231 cells:  Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction.  J Immunol.  1995; 155:3830-3838.

Foreman KE, Wrone-Smith T, Boise LH, Thompson CB, Polverini PJ, Simonian PL, Nunez G and Nickloff BJ.  Kaposi’s sarcoma tumor cells preferentially express Bcl-XL.  Am J Path.  1996; 149:795-803.

Nunez G, Merino R, Simonian PL and Grillot DA.  Regulation of lymphoid apoptosis by Bcl-2 and Bcl-XL.  Adv Exp Med & Biol.  1996; 406:75-82.

Bojes HK, Datta K, Xu J, Chin A, Simonian P, Nunez G and Kehrer JP.  Bcl-XL overexpression attenuates glutathione depletion in FL5.12 cells following interleukin-3 withdrawal.  Bichem J.  1997; 325:315-319.

Mitra RS, Wrone-Smith T, Simonian P, Foreman KE, Nunez G and Nickloff BJ.  Apoptosis in keratinocytes is not dependent on induction of differentiation.  Lab Invest.  1997; 76:99-107.

Raghu G, Pierre-Jerome M, Dordal MS, Simonian P, Bauer KD and Winter JN.  P-glycoprotein and alterations in the glutathione/glutathione peroxidase cycle underlie doxorubicin in HL-60-R, a subclone of the HL-60 human leukemia cell line.  Int J Cancer.  1993; 53:804-811.

George A, Sabsay B, Simonian P and Veis A.  Characterization of a novel dentin matrix acidic phosphoprotein.  Implications of induction of biomineralization.  J Biol Chem.  1993; 268:12624-12630.